Request Trial
shutterstock_1395147236_poptika
Poptika / Shutterstock.com
15 December 2020PharmaSally Shorthose and Rumana Khanom

What 2020 means for the life sciences

2020 has been a tumultuous year in many respects and the conflation of a pandemic and the impact of the UK’s departure from the EU has profound implications for the life sciences and medical devices industries in the UK and the EU. In this article, we consider how and why these events will have such an effect and how affected businesses may need to prepare for these.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026   Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026   The decision leaves a $177 million verdict against Lilly intact, but a dissenting judge has warned the ruling could “undermine medical innovation” by allowing overly broad patent claims to survive and provide a way around the Supreme Court’s Amgen decision.
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026   Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?
Lilly loses Fed Circ rehearing bid, sparking enablement questions
Takeda sees off UK challenge to Elvanse SPC
Conley Rose welcomes back former employee with legal and business nous
Mylan throws down new gauntlet in Novo Wegovy patent fight
Novartis defeats Orange Book challenge but suffers EU setback